Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed Dose TACT (ALAQ) vs ACTs for Uncomplicated P. falciparum Malaria
NCT05951595Phase 3Recruiting
- Sponsor
- University of Oxford
- Start
- Sep 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of artemether + lumefantrine + amodiaquine in Plasmodium falciparum malaria, sponsored by University of Oxford. Started Sep 2025; status: recruiting.
02
Drugs
artemether + lumefantrine + amodiaquine
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT05951595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05951595.